Serum anti-myomeglin antibodies is a useful tumor marker to detect gastrointestinal cancer

为了寻找新的食管鳞状细胞癌（SCC）血清学标志物，我们应用重组cDNA表达克隆（SEREX）技术对SCC抗原进行了血清学鉴定。E.以食管癌细胞株（T.Tn）的mRNA为模板构建λ ZAP Ⅱ噬菌体cDNA文库，感染大肠杆菌，筛选IPTG诱导的cDNA产物，并检测其与食管鳞癌患者异基因血清中抗体的相互作用。我们确定了myomegalin（磷酸二酯酶4D相互作用蛋白/PDE 4DIP）作为食管SCC的新SEREX抗原。免疫印迹分析显示，血清抗-myomegalin抗体（s-myomegalin-Abs）存在于43的91（47%）患者，但只有一个45（2.2%）健康对照。38%的I期患者存在抗肌巨蛋白抗体。s-myomegalin-Abs的阳性率最高。虽然s-myomegalin-Abs的存在与患者的任何临床病理特征无关，但多因素分析表明，s-myomegalin-Abs的存在与良好的预后显著相关

In order to identify new serum markers of esophageal squamous cell carcinoma (SCC), we performed serological identification of antigens by recombinant cDNA expression cloning (SEREX). E. coli was infected with λZAPII phage cDNA library prepared from mRNA of an esophageal cancer cell line (T.Tn), and IPTG-induced cDNA products were screened for interaction with antibodies in allogeneic sera of patients with esophageal SCC. We identified myomegalin (phosphodiesterase 4D interacting protein/PDE4DIP) as a new SEREX antigen for esophageal SCC. Western blotting analysis revealed that serum anti-myomegalin antibodies (s-myomegalin-Abs) were present in 43 out of 91 (47%) patients but in only one out of 45 (2.2%) healthy controls. Anti-myomegalin Abs were present 38% of stage I patients. The positive rate of s-myomegalin-Abs was the highest among the other conventional tumor markers. Although the presence of s-myomegalin-Abs was not related to any of clinicopathological features of the patients concerned, multivariate analysis indicated that presence of s-myomegalin-Abs was significantly associated with favorable prognosis